Davies Michael A
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adv Pharmacol. 2012;65:109-42. doi: 10.1016/B978-0-12-397927-8.00005-1.
The prevention and treatment of brain metastases is an increasingly important challenge in oncology. Improved understanding of the molecular pathogenesis of a number of cancers has led to the development of highly active targeted therapies for patients with specific oncogenic events. Such therapies include EGFR inhibitors for lung cancer, HER2/neu inhibitors for breast cancer, and BRAF inhibitors for melanoma. This review will discuss the development of these targeted therapy approaches, existing data about their role in the management of brain metastasis, and opportunities and challenges for future research in this critical area.
脑转移瘤的预防和治疗是肿瘤学中一个日益重要的挑战。对多种癌症分子发病机制的深入了解，促使针对特定致癌事件的患者开发出了高活性的靶向治疗方法。此类治疗包括用于肺癌的表皮生长因子受体（EGFR）抑制剂、用于乳腺癌的人表皮生长因子受体2/神经（HER2/neu）抑制剂以及用于黑色素瘤的BRAF抑制剂。本综述将讨论这些靶向治疗方法的发展、它们在脑转移瘤管理中作用的现有数据，以及这一关键领域未来研究的机遇与挑战。
